Investors | Co-Diagnostics, Inc.

SEC Filings

NASDAQCODX

Year

View

Form	Description	Date	Format
DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	Jun 22, 2021	Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
DEFA14A	Additional proxy soliciting materials - definitive	Nov 3, 2020	Open Additional proxy soliciting materials - definitive in HTML.Open Additional proxy soliciting materials - definitive in DOC file.Open Additional proxy soliciting materials - definitive in PDF file.Open Additional proxy soliciting materials - definitive in XLS file.
DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	Nov 3, 2020	Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

Site Terms and Conditions

Privacy Policy